ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel
  • »
  • Health»
  • Personal Health Information & Self-Help

Belimumab (Benlysta): The First New Drug For Systemic Lupus Erythematosus Since 1955

Updated on April 21, 2015
Microscopic image of changes to a lymph node brought about by systemic lupus erythematosus.
Microscopic image of changes to a lymph node brought about by systemic lupus erythematosus. | Source

Introduction

Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune disease that can affect organs and tissue throughout the body. Most frequently, it shows up in the skin, joints, blood and kidneys. According to the University of Maryland Medical Center, two types of immune cells,T-lymphocytes or T-cells and B-lymphocytes or B-cells, are involved in the cause of SLE. T-cells and B-cells secrete cytokines, proteins that carry signals to neighboring cells to coordinate the immune response of the body to a particular antigen. Scientists believe that in people with SLE, cytokines are overexpressed and this leads to hyperactivity of T-cells and B-cells. The overactive B-cells eventually produce abnormal antibodies that go beyond the usual scope of antibody recognition. Healthy tissues are mistakenly identified as invading organisms, and the overactive immune cells initiate an inflammatory response against the healthy tissues.

Information on Belimumab (Benlysta)

Belimumab was approved as a treatment for systemic lupus erythematosus (SLE) by the U.S. Food and Drug Administration in March 2011. It is in a class of drugs called monoclonal antibodies, and is administered by intravenous infusion. Belimumab is the first new treatment for SLE since 1955 when the FDA approved Plaquenil and corticosteroids. It works by blocking the binding of B-cell stimulator protein, a cytokine, to receptors on the B-cells. This has the effect of limiting the number of overactive B-cells that differentiate into plasma cells responsible for the production of harmful abnormal antibodies.

The efficacy of belimumab was demonstrated in a phase 3 clinical study of 867 patients with active systemic lupus erythematosus. The results of this study were published in the February 26, 2011, issue of "The Lancet." Patients were treated with standard corticosteroid therapy combined with once monthly i.v. infusion of belimumab over the course of one year, and evaluated primarily by improvements in their Systemic Lupus Erythematosus Responder Index (SRI), a method of assessing disease activity in SLE patients. Results of the study showed that patients taking belimumab with standard care had significantly higher SRI rates relative to those on standard care plus placebo. This means that there was a general decrease in disease activity in patients taking belimumab. In addition, a secondary criterion of efficacy was reduction in the use of the corticosteroid prednisone. When the results of this phase 3 study were analyzed with those of a second phase 3 trial, it was clear that a significantly greater number of patients on belimumab were able to reduce their use of prednisone relative to patients on placebo.

Generally speaking, belimumab has been relatively well tolerated in clinical trials.The most common side effects include infusion-site reactions, nausea, diarrhea, fever, sore throat, bronchitis, insomnia, pain in the extemities, depression and migraine. ln clinical trials, more deaths and serious infections occurred in patients taking belimumab relative to those on placebo. For this reason, physicians need to exercise caution in prescribing belimumab to patients with chronic infections. Patients who develop an infection while taking belimumab should seriously consider stopping treatment.

What Benlysta Means for Lupus R & D

Disclaimer

This hub has been written for the sole purpose of providing information to the reader. It is not intended to be a source of any kind of medical advice or instruction, and it should not be used in the diagnosis of any illness, disease or condition. You should consult your doctor if you have questions about a specific medical problem.

Comments

    0 of 8192 characters used
    Post Comment

    No comments yet.

    working

    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, hubpages.com uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at: "https://hubpages.com/privacy-policy#gdpr"

    Show Details
    Necessary
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the googleapis.com or gstatic.com domains, for performance and efficiency reasons. (Privacy Policy)
    Features
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Marketing
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Statistics
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)